E-mail List
Program On Regulation, Therapeutics And Law (PORTAL) Division of Pharmacoepidemiology and Pharmacoeconomics 1620 Tremont Street, Suite 3030 Boston, MA 02120
Related Articles
अमेरिकन सोसाइटी अफ क्लिनिकल अंकोलोजीबाट फेलोसिप पाउने पहिलो नेपाली चिकित्सक बने डा. विशाल ज्ञवाली
काठमाडौँ, २१ मंसिर । नेपालका युवा अंकालोजिष्ट डा विशाल ज्ञवालीले संसारकै प्रसिद्ध मानिने अमेरिकन सोसाइटी अफ क्लिनिकल अंकोलोजीमा फेलोसिप प्राप्त गरेका छन् । हाल क्यानडाको…
अमेरिकन सोसाइटी अफ क्लिनिकल अंकोलोजीबाट फेलोसिप पाउने पहिलो नेपाली चिकित्सक बने डा. विशाल ज्ञवाली
काठमाडौँ, २१ मंसिर । नेपालका युवा अंकालोजिष्ट डा विशाल ज्ञवालीले संसारकै प्रसिद्ध मानिने अमेरिकन सोसाइटी अफ क्लिनिकल अंकोलोजीमा फेलोसिप प्राप्त गरेका छन् । हाल क्यानडाको…
Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis
Several factors informed HTA outcomes for new cancer medicines. A high ESMO-MCBS score, defined as indicating substantial clinical benefit, increased the likelihood of a positive…
At ASCO, the Cancer Community Hyped the Wrong Trial
Oncologist Bishal Gyawali, MD, PhD, highlights concerns surrounding which trials the oncology community is choosing to celebrate.
At ASCO, the Cancer Community Hyped the Wrong Trial
Oncologist Bishal Gyawali, MD, PhD, highlights concerns surrounding which trials the oncology community is choosing to celebrate.
At ASCO, the Cancer Community Hyped the Wrong Trial
Oncologist Bishal Gyawali, MD, PhD, highlights concerns surrounding which trials the oncology community is choosing to celebrate.
Man dismissed as ‘fat’ and given Ozempic before doctors find 60-pound…
Thomas Kraut, 59, was diagnosed as obese. After 12 years, a doctor finally realized that his rapidly growing belly actually had a nearly 21-inch tumor…
What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study,…
What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study,…
What constitutes meaningful benefit of cancer drugs in the context of LMICs? A mixed-methods study of oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs
The importance of surrogate endpoints, magnitude of clinical benefit of cancer drugs, and their prices have often been debated in the oncology world. No study,…